Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

被引：0
作者：
O. Juan
J. Vidal
R. Gisbert
J. Muñoz
S. Maciá
J. Gómez-Codina
机构：
[1] Hospital Universitari I Politècnic La Fe,Medical Oncology Department
[2] Hospital Arnau de Vilanova,Clinical Laboratory
[3] Hospital Dr Peset,Medical Oncology Department
[4] Hospital General de Elda,Medical Oncology Department
来源：
Clinical and Translational Oncology | 2014年 / 16卷
关键词：
Lung cancer; Circulating tumor cells; Prognosis; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：637 / 643
页数：6
相关论文
共 50 条
[41]   Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy [J].
Najjar, Fadi ;
Alammar, Moosheer ;
Bachour, Marroan ;
Almalla, Nissreen ;
Altahan, Moaz ;
Alali, Ali ;
Al-Massarani, Ghassan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (01) :119-125
[42]   Gemcitabine/carboplatin in advanced non-small cell lung cancer [J].
Zatloukal, P ;
Petruzelka, L .
LUNG CANCER, 2002, 38 :S33-S36
[43]   Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece [J].
Maniadakis, N. ;
Fragoulakis, V. ;
Pallis, A. ;
Prezerakos, P. ;
Georgoulias, V. .
LUNG CANCER, 2007, 58 (02) :275-281
[44]   Clinical significance of circulating tumor cells in patients with small-cell lung cancer [J].
Wang, Yu-Li ;
Liu, Chun-Hua ;
Li, Jing ;
Ma, Xiao-Ping ;
Gong, Ping .
TUMORI JOURNAL, 2017, 103 (03) :242-248
[45]   Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer [J].
Tong, Bing ;
Xu, Yan ;
Zhao, Jing ;
Chen, Minjiang ;
Zhong, Wei ;
Xing, Jia ;
Wang, Mengzhao .
THORACIC CANCER, 2018, 9 (05) :640-645
[46]   Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: A phase II study [J].
Syrigos, K. N. ;
Karapanagiotou, E. ;
Charpidou, A. ;
Dilana, K. ;
Dannos, I. ;
Dionellis, G. ;
Rigopoulou, A. ;
Georgatou, N. ;
Roussos, C. .
JOURNAL OF CHEMOTHERAPY, 2007, 19 (04) :438-443
[47]   Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer [J].
Xu, Chun-Hua ;
Yang, Yang ;
Wang, Yu-Chao ;
Yan, Jun ;
Qian, Li-Hua .
ONCOTARGET, 2017, 8 (14) :22483-22489
[48]   Tumor markers as prognostic factors in treated non-small cell lung cancer [J].
Trapé, J ;
Buxo, J ;
De Olaguer, JP ;
Vidal, C .
ANTICANCER RESEARCH, 2003, 23 (5B) :4277-4281
[49]   Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: A phase I study [J].
Frassineti, GL ;
Ibrahim, T ;
Zoli, W ;
Monti, M ;
Ricotti, L ;
Nanni, O ;
Amadori, D .
TUMORI JOURNAL, 2002, 88 (02) :99-103
[50]   The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study [J].
MacDougall, Kira ;
Niazi, Muhammad Rafay Khan ;
Hosry, Jeff ;
Homsy, Sylvester ;
Bershadskiy, Alexander .
ONCOLOGY-NEW YORK, 2022, 36 (03) :156-161
12345